Roy C Martin1, Edward Faught2, Jerzy P Szaflarski1, Joshua Richman3, Ellen Funkhouser4, Kendra Piper5, Lucia Juarez4, Chen Dai4, Maria Pisu4. 1. Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, U.S.A. 2. Department of Neurology, Emory University, Atlanta, Georgia, U.S.A. 3. Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, U.S.A. 4. Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, U.S.A. 5. Department of Gynecology and Obstetrics, Emory University, Atlanta, Georgia, U.S.A.
Abstract
OBJECTIVE: Disparities in epilepsy treatment are not uncommon; therefore, we examined population-based estimates of initial antiepileptic drugs (AEDs) in new-onset epilepsy among racial/ethnic minority groups of older US Medicare beneficiaries. METHODS: We conducted retrospective analyses of 2008-2010 Medicare administrative claims for a 5% random sample of beneficiaries augmented for minority representation. New-onset epilepsy cases in 2009 had ≥1 International Classification of Diseases, Ninth Revision (ICD-9) 345.x or ≥2 ICD-9 780.3x, and ≥1 AED, AND no seizure/epilepsy claim codes or AEDs in preceding 365 days. We examined AED use and concordance with Quality Indicators of Epilepsy Treatment (QUIET) 6 (monotherapy as initial treatment = ≥30 day first prescription with no other concomitant AEDs), and prompt AED treatment (first AED within 30 days of diagnosis). Logistic regression examined likelihood of prompt treatment by demographic (race/ethnicity, gender, age), clinical (number of comorbid conditions, neurology care, index event occurring in the emergency room (ER)), and economic (Part D coverage phase, eligibility for Part D Low Income Subsidy [LIS], and ZIP code level poverty) factors. RESULTS: Over 1 year of follow-up, 79.6% of 3,706 new epilepsy cases had one AED only (77.89% of whites vs. 89% of American Indian/Alaska Native [AI/AN]). Levetiracetam was the most commonly prescribed AED (45.5%: from 24.6% AI/AN to 55.0% whites). The second most common was phenytoin (30.6%: from 18.8% Asians to 43.1% AI/AN). QUIET 6 concordance was 94.7% (93.9% for whites to 97.3% of AI/AN). Only 50% received prompt AED therapy (49.6% whites to 53.9% AI/AN). Race/ethnicity was not significantly associated with AED patterns, monotherapy use, or prompt treatment. SIGNIFICANCE: Monotherapy is common across all racial/ethnic groups of older adults with new-onset epilepsy, older AEDs are commonly prescribed, and treatment is frequently delayed. Further studies on reasons for treatment delays are warranted. Interventions should be developed and tested to develop paradigms that lead to better care. Wiley Periodicals, Inc.
OBJECTIVE: Disparities in epilepsy treatment are not uncommon; therefore, we examined population-based estimates of initial antiepileptic drugs (AEDs) in new-onset epilepsy among racial/ethnic minority groups of older US Medicare beneficiaries. METHODS: We conducted retrospective analyses of 2008-2010 Medicare administrative claims for a 5% random sample of beneficiaries augmented for minority representation. New-onset epilepsy cases in 2009 had ≥1 International Classification of Diseases, Ninth Revision (ICD-9) 345.x or ≥2 ICD-9 780.3x, and ≥1 AED, AND no seizure/epilepsy claim codes or AEDs in preceding 365 days. We examined AED use and concordance with Quality Indicators of Epilepsy Treatment (QUIET) 6 (monotherapy as initial treatment = ≥30 day first prescription with no other concomitant AEDs), and prompt AED treatment (first AED within 30 days of diagnosis). Logistic regression examined likelihood of prompt treatment by demographic (race/ethnicity, gender, age), clinical (number of comorbid conditions, neurology care, index event occurring in the emergency room (ER)), and economic (Part D coverage phase, eligibility for Part D Low Income Subsidy [LIS], and ZIP code level poverty) factors. RESULTS: Over 1 year of follow-up, 79.6% of 3,706 new epilepsy cases had one AED only (77.89% of whites vs. 89% of American Indian/Alaska Native [AI/AN]). Levetiracetam was the most commonly prescribed AED (45.5%: from 24.6% AI/AN to 55.0% whites). The second most common was phenytoin (30.6%: from 18.8% Asians to 43.1% AI/AN). QUIET 6 concordance was 94.7% (93.9% for whites to 97.3% of AI/AN). Only 50% received prompt AED therapy (49.6% whites to 53.9% AI/AN). Race/ethnicity was not significantly associated with AED patterns, monotherapy use, or prompt treatment. SIGNIFICANCE: Monotherapy is common across all racial/ethnic groups of older adults with new-onset epilepsy, older AEDs are commonly prescribed, and treatment is frequently delayed. Further studies on reasons for treatment delays are warranted. Interventions should be developed and tested to develop paradigms that lead to better care. Wiley Periodicals, Inc.
Authors: M J V Pugh; D R Berlowitz; G Montouris; B Bokhour; J A Cramer; V Bohm; M Bollinger; S Helmers; A Ettinger; K J Meador; N Fountain; J Boggs; W O Tatum; J Knoefel; C Harden; R H Mattson; L Kazis Journal: Neurology Date: 2007-10-10 Impact factor: 9.910
Authors: Teresa M Waters; Cyril F Chang; William T Cecil; Panagiotis Kasteridis; David Mirvis Journal: Health Serv Res Date: 2010-10-28 Impact factor: 3.402
Authors: E Wayne Holden; Elizabeth Grossman; Hoang Thanh Nguyen; Margaret J Gunter; Becky Grebosky; Ann Von Worley; Leila Nelson; Scott Robinson; David J Thurman Journal: Dis Manag Date: 2005-02
Authors: Omotola A Hope; John E Zeber; Nancy R Kressin; Barbara G Bokhour; Anne C Vancott; Joyce A Cramer; Megan E Amuan; Janice E Knoefel; Mary Jo Pugh Journal: Epilepsia Date: 2008-11-17 Impact factor: 5.864
Authors: Laurel A Copeland; Alan B Ettinger; John E Zeber; Jodi M Gonzalez; Mary Jo Pugh Journal: BMC Health Serv Res Date: 2011-04-19 Impact factor: 2.655
Authors: Maria Pisu; Joshua Richman; Jerzy P Szaflarski; Ellen Funkhouser; Chen Dai; Lucia Juarez; Edward Faught; Roy C Martin Journal: Epilepsia Date: 2019-06-06 Impact factor: 5.864
Authors: Jerzy P Szaflarski; Roy C Martin; Edward Faught; Ellen Funkhouser; Joshua Richman; Kendra Piper; Lucia Juarez; Chen Dai; Maria Pisu Journal: Epilepsy Behav Date: 2017-04-12 Impact factor: 2.937
Authors: Samuel Waller Terman; Chun C Lin; Wesley T Kerr; Lindsey B DeLott; Brian C Callaghan; James F Burke Journal: Neurology Date: 2022-06-15 Impact factor: 11.800
Authors: Edward Faught; Jerzy P Szaflarski; Joshua Richman; Ellen Funkhouser; Roy C Martin; Kendra Piper; Chen Dai; Lucia Juarez; Maria Pisu Journal: Epilepsia Date: 2018-02-07 Impact factor: 5.864